Evidence map›Paper›PMID 40214871›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Mitochondria-tropic radioconjugates to enhance the therapeutic potential of terbium-161.

Joana F Santos, Camille Van Laere, Catarina D Silva, Irwin Cassells, Célia Fernandes, Paula Raposinho, Ana Belchior, Catarina I G Pinto, Filipa Mendes, Christopher Cawthorne and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Development and In Vitro Evaluation of [International journal of molecular sciences · 2025
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Joana F SantosC2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, 2695-066, Portugal.
Camille Van LaereNuclear Medical Applications, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium.
Catarina D SilvaC2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, 2695-066, Portugal.
Irwin CassellsNuclear Medical Applications, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium.
Célia FernandesC2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, 2695-066, Portugal.
Paula RaposinhoC2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, 2695-066, Portugal.
Ana BelchiorC2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, 2695-066, Portugal.
Catarina I G PintoC2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, 2695-066, Portugal.
Filipa MendesC2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, 2695-066, Portugal.
Christopher CawthorneNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium.
Maarten OomsNuclear Medical Applications, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium.
Michiel Van de VoordeNuclear Medical Applications, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium.
Frederik CleerenLaboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, B-3000, Belgium. frederik.cleeren@kuleuven.be.
António PauloC2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bobadela LRS, 2695-066, Portugal. apaulo@ctn.tecnico.ulisboa.pt.ORCID http://orcid.org/0000-0002-9164-0913

Funding

Fonds Wetenschappelijk OnderzoekFundação para a Ciência e a Tecnologia 2020.07119.BDFundação para a Ciência e a Tecnologia PRT/BD/154612/2023Fundação para a Ciência e a Tecnologia PRT/BD/154625/2023Fundação para a Ciência e a Tecnologia PTDC/MED-QUI/1554/2020Fundação para a Ciência e a Tecnologia UID/Multi/04349/2019H2020 European Research Council 101008571
6 · The paper itself

Abstract

backgroundStrategies that focus on delivering Auger electron emitters to highly radiosensitive intracellular targets-such as the nucleus, cell membrane, or mitochondria-are gaining attention. Targeting these organelles could enhance therapeutic efficacy while minimizing off-target toxicity by allowing lower administered doses. In this context, this study explores the therapeutic potential of

resultsTwo novel radiocomplexes, [

conclusionsThe TPP-modified

Indexed as

161Tb-radiocomplexesAuger electronsMitochondriaProstate cancerPSMA

Identifiers

PMID40214871
PMCPMC11992321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.